Tango Therapeutics Inc at Guggenheim Synthetic Lethality Day (Virtual) Transcript
(audio in progress) for joining us for our next session. I'm Charles Zhu, one of the senior biotech analysts here at Guggenheim Securities. With me here today, or with us here today, is Barbara Weber, Chief Executive Officer of Tango Therapeutics. Barbara, thank you very much for coming on with us this morning. Just to kick us off, could you perhaps provide us a two to three minute introduction and overview to Tango, your platform, as well as your pipeline?
Good morning, Charles, and thank you for having us. Tango Therapeutics is a precision oncology company that is focused on using the genetic principle of synthetic lethality to discover novel targets and novel ways to use existing drugs. The interest in Tango really stems from my long background working actually in BRCA1 and 2 on the isolation and cloning and characterization of both genes. And the realization that once they were identified, they couldn't be used as drug targets because like all tumor suppressor
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
